Blog

Latest pharma industry updates by Nicolas Schmitz

Photo of Nicolas Schmitz taken from LinkedIn

Jan 12, 2024, 17:07

Latest pharma industry updates by Nicolas Schmitz

Nicolas Schmitz,

“Latest pharma industry updates:

Pharma stocks globally faced a challenging 2023, with only anti-obesity Eli Lilly and Company and Novo Nordisk shining.
Goldman Sachs closes a $650M fund for life sciences investments, one of the largest first-time private funds in the sector.
Longboard Pharmaceuticals shares surge 316% after promising data from bexicaserin study for developmental and epileptic encephalopathies.
Esperion amends collaboration with Daiichi Sankyo, Inc. resolving disputes with a $125 million agreement.
Roche partners with Remix Therapeutics, exploring new RNA-targeting drugs, the third such deal following Arrakis and Ribometrix.
Pfizer secures Canadian approval for its first gene therapy, Beqvez, for hemophilia B.
Eli Lilly and Company launches “LillyDirect,” an online service in the U.S. for obesity, migraine, and diabetes treatments, including delivery and telehealth support.
Dermata Therapeutics, Inc. shares rise 113% after securing a new patent in Japan for DMT410 in hyperhidrosis treatment.
Novo Nordisk announces research partnerships with Omega Therapeutics and Cellarity for obesity and NASH treatments.
Boehringer Ingelheim collaborates with Ribocure Pharmaceuticals AB to develop RNAi-based liver disease treatments, including NASH.
Merck CEO Robert Davis highlights GLP-1 treatments with benefits beyond weight loss, citing efinopegdutide’s potential in NASH.
Evotec CEO Werner Lanthaler resigns after a challenging year, leading to a 20% drop in company’s stock.
Innate Pharma’s lacutamab trial resumes post-FDA investigation into a patient’s death.
Allogene Therapeutics plans strategic shift to improve CAR-T therapy use in earlier treatment stages.
Lykos Therapeutics (formerly MAPS PBC) raises over $100M for MDMA-based PTSD therapy, eyeing FDA approval.
Intellia Therapeutics, Inc. announces layoffs and research cuts, focusing on priority drug programs.
Roche signs $50M ADC deal with a Chinese biotech, continuing its expansion in the field.
Roche secures a $66M deal with MOMA Therapeutics, the third significant pact of the week
Nemaura Pharma Limited opts for delisting from Nasdaq, moving to OTC Markets, with shares falling 32%.”

Source: Nicolas Schmitz/LinkedIn

Allogene Therapeutics Arrakis Beqvez bexicaserin Boehringer Ingelheim cancer Cellarity Daiichi Sankyo Dermata Therapeutics DMT410 efinopegdutide Eli Lilly and Company Esperion Goldman Sachs Inc Innate Pharma Intellia Therapeutics KBI Biopharma LillyDirect Longboard Pharmaceuticals Lykos Therapeutics Nemaura Pharma Limited Nicolas Schmitz Novo Nordisk Omega Therapeutics OncoDaily Oncology pfizer Remix Therapeutics Ribocure Pharmaceuticals AB Ribometrix Robert Davis Roche Werner Lanthaler

100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 10

OncoThon 2024 Raises $1.3 Million for Pediatric Cancer Research

Remembering Virgil Abloh: Louis Vuitton’s Creative Director Honored at 41 After His Brave Battle with Cardiac Angiosarcoma

Richard Sullivan: The State of Global Cancer Surgery from Political and Equity Perspectives

Immunotherapy for Bladder Cancer: Types, Success Rate, Side Effects & More

Special Coverage